A citation-based method for searching scientific literature

Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards, Anne Rosser, Holly B Kordasiewicz, Christian Czech, Eric E Swayze, Daniel A Norris, Tiffany Baumann, Irene Gerlach, Scott A Schobel, Erika Paz, Anne V Smith, C Frank Bennett, Roger M Lane. N Engl J Med 2019
Times Cited: 219







List of co-cited articles
1066 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
Holly B Kordasiewicz, Lisa M Stanek, Edward V Wancewicz, Curt Mazur, Melissa M McAlonis, Kimberly A Pytel, Jonathan W Artates, Andreas Weiss, Seng H Cheng, Lamya S Shihabuddin,[...]. Neuron 2012
437
24

Huntington disease.
Gillian P Bates, Ray Dorsey, James F Gusella, Michael R Hayden, Chris Kay, Blair R Leavitt, Martha Nance, Christopher A Ross, Rachael I Scahill, Ronald Wetzel,[...]. Nat Rev Dis Primers 2015
516
20

The Biology of Huntingtin.
Frédéric Saudou, Sandrine Humbert. Neuron 2016
322
18

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Richard S Finkel, Eugenio Mercuri, Basil T Darras, Anne M Connolly, Nancy L Kuntz, Janbernd Kirschner, Claudia A Chiriboga, Kayoko Saito, Laurent Servais, Eduardo Tizzano,[...]. N Engl J Med 2017
708
15

Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Sarah J Tabrizi, Rhia Ghosh, Blair R Leavitt. Neuron 2019
55
27

Therapies targeting DNA and RNA in Huntington's disease.
Edward J Wild, Sarah J Tabrizi. Lancet Neurol 2017
120
14

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Eugenio Mercuri, Basil T Darras, Claudia A Chiriboga, John W Day, Craig Campbell, Anne M Connolly, Susan T Iannaccone, Janbernd Kirschner, Nancy L Kuntz, Kayoko Saito,[...]. N Engl J Med 2018
476
13

Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
Amber L Southwell, Holly B Kordasiewicz, Douglas Langbehn, Niels H Skotte, Matthew P Parsons, Erika B Villanueva, Nicholas S Caron, Michael E Østergaard, Lisa M Anderson, Yuanyun Xie,[...]. Sci Transl Med 2018
49
26

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.
Bryan Zeitler, Steven Froelich, Kimberly Marlen, David A Shivak, Qi Yu, Davis Li, Jocelynn R Pearl, Jeffrey C Miller, Lei Zhang, David E Paschon,[...]. Nat Med 2019
52
25

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Timothy M Miller, Alan Pestronk, William David, Jeffrey Rothstein, Ericka Simpson, Stanley H Appel, Patricia L Andres, Katy Mahoney, Peggy Allred, Katie Alexander,[...]. Lancet Neurol 2013
380
12

Huntington disease: natural history, biomarkers and prospects for therapeutics.
Christopher A Ross, Elizabeth H Aylward, Edward J Wild, Douglas R Langbehn, Jeffrey D Long, John H Warner, Rachael I Scahill, Blair R Leavitt, Julie C Stout, Jane S Paulsen,[...]. Nat Rev Neurol 2014
498
11

CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Su Yang, Renbao Chang, Huiming Yang, Ting Zhao, Yan Hong, Ha Eun Kong, Xiaobo Sun, Zhaohui Qin, Peng Jin, Shihua Li,[...]. J Clin Invest 2017
148
10

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Richard S Finkel, Claudia A Chiriboga, Jiri Vajsar, John W Day, Jacqueline Montes, Darryl C De Vivo, Mason Yamashita, Frank Rigo, Gene Hung, Eugene Schneider,[...]. Lancet 2016
475
10

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
Ryan L Boudreau, Jodi L McBride, Inês Martins, Shihao Shen, Yi Xing, Barrie J Carter, Beverly L Davidson. Mol Ther 2009
237
10

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.
J Nasir, S B Floresco, J R O'Kusky, V M Diewert, J M Richman, J Zeisler, A Borowski, J D Marth, A G Phillips, M R Hayden. Cell 1995
578
10

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.
Jodi L McBride, Mark R Pitzer, Ryan L Boudreau, Brett Dufour, Theodore Hobbs, Sergio R Ojeda, Beverly L Davidson. Mol Ther 2011
147
9

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system.
Julia F Alterman, Bruno M D C Godinho, Matthew R Hassler, Chantal M Ferguson, Dimas Echeverria, Ellen Sapp, Reka A Haraszti, Andrew H Coles, Faith Conroy, Rachael Miller,[...]. Nat Biotechnol 2019
33
27

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
L Mangiarini, K Sathasivam, M Seller, B Cozens, A Harper, C Hetherington, M Lawton, Y Trottier, H Lehrach, S W Davies,[...]. Cell 1996
9

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Richard Grondin, Michael D Kaytor, Yi Ai, Peter T Nelson, Deepak R Thakker, Jennifer Heisel, Marcy R Weatherspoon, Janelle L Blum, Eric N Burright, Zhiming Zhang,[...]. Brain 2012
96
9


Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, Peter M Andersen, Nazem Atassi, Robert C Bucelli, Angela Genge, Jonathan Glass, Shafeeq Ladha, Albert L Ludolph,[...]. N Engl J Med 2020
73
12

Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
Michelle Gray, Dyna I Shirasaki, Carlos Cepeda, Véronique M André, Brian Wilburn, Xiao-Hong Lu, Jifang Tao, Irene Yamazaki, Shi-Hua Li, Yi E Sun,[...]. J Neurosci 2008
414
8

Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
C Frank Bennett, Adrian R Krainer, Don W Cleveland. Annu Rev Neurosci 2019
54
14

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Claudia A Chiriboga, Kathryn J Swoboda, Basil T Darras, Susan T Iannaccone, Jacqueline Montes, Darryl C De Vivo, Daniel A Norris, C Frank Bennett, Kathie M Bishop. Neurology 2016
318
8

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
140
8


Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Lisa M Stanek, Wendy Yang, Stuart Angus, Pablo S Sardi, Michael R Hayden, Gene H Hung, C Frank Bennett, Seng H Cheng, Lamya S Shihabuddin. J Huntingtons Dis 2013
43
18

In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.
Amber L Southwell, Niels H Skotte, Holly B Kordasiewicz, Michael E Østergaard, Andrew T Watt, Jeffrey B Carroll, Crystal N Doty, Erika B Villanueva, Eugenia Petoukhov, Kuljeet Vaid,[...]. Mol Ther 2014
84
9

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.
Jiaxin Hu, Masayuki Matsui, Keith T Gagnon, Jacob C Schwartz, Sylvie Gabillet, Khalil Arar, Jun Wu, Ilya Bezprozvanny, David R Corey. Nat Biotechnol 2009
171
8

The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.
Nicole A Datson, Anchel González-Barriga, Eleni Kourkouta, Rudie Weij, Jeroen van de Giessen, Susan Mulders, Outi Kontkanen, Taneli Heikkinen, Kimmo Lehtimäki, Judith C T van Deutekom. PLoS One 2017
31
25

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Jeffrey B Carroll, Simon C Warby, Amber L Southwell, Crystal N Doty, Sarah Greenlee, Niels Skotte, Gene Hung, C Frank Bennett, Susan M Freier, Michael R Hayden. Mol Ther 2011
173
8

Sustained effects of nonallele-specific Huntingtin silencing.
Valérie Drouet, Valérie Perrin, Raymonde Hassig, Noëlle Dufour, Gwennaelle Auregan, Sandro Alves, Gilles Bonvento, Emmanuel Brouillet, Ruth Luthi-Carter, Philippe Hantraye,[...]. Ann Neurol 2009
161
8

RNA-Targeted Therapeutics.
Stanley T Crooke, Joseph L Witztum, C Frank Bennett, Brenda F Baker. Cell Metab 2018
235
8


Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
Edward J Wild, Roberto Boggio, Douglas Langbehn, Nicola Robertson, Salman Haider, James R C Miller, Henrik Zetterberg, Blair R Leavitt, Rainer Kuhn, Sarah J Tabrizi,[...]. J Clin Invest 2015
113
8

Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
Dongbo Yu, Hannah Pendergraff, Jing Liu, Holly B Kordasiewicz, Don W Cleveland, Eric E Swayze, Walt F Lima, Stanley T Crooke, Thazha P Prakash, David R Corey. Cell 2012
182
8

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Sarah J Tabrizi, Rachael I Scahill, Gail Owen, Alexandra Durr, Blair R Leavitt, Raymund A Roos, Beth Borowsky, Bernhard Landwehrmeyer, Chris Frost, Hans Johnson,[...]. Lancet Neurol 2013
469
8

Spinocerebellar ataxias: prospects and challenges for therapy development.
Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
70
10

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
Hayley S McLoughlin, Lauren R Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G Blumenstein, Hien Zhao, Holly B Kordasiewicz, Vikram G Shakkottai, Henry L Paulson. Ann Neurol 2018
58
12

Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
Lindsay A Becker, Brenda Huang, Gregor Bieri, Rosanna Ma, David A Knowles, Paymaan Jafar-Nejad, James Messing, Hong Joo Kim, Armand Soriano, Georg Auburger,[...]. Nature 2017
222
7

Huntington's disease: from molecular pathogenesis to clinical treatment.
Christopher A Ross, Sarah J Tabrizi. Lancet Neurol 2011
858
7

Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.
Jillian Friedrich, Holly B Kordasiewicz, Brennon O'Callaghan, Hillary P Handler, Carmen Wagener, Lisa Duvick, Eric E Swayze, Orion Rainwater, Bente Hofstra, Michael Benneyworth,[...]. JCI Insight 2018
39
17

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue.
S Zeitlin, J P Liu, D L Chapman, V E Papaioannou, A Efstratiadis. Nat Genet 1995
545
7

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.
Jana Miniarikova, Ilaria Zanella, Angelina Huseinovic, Tom van der Zon, Evelyn Hanemaaijer, Raygene Martier, Annemart Koornneef, Amber L Southwell, Michael R Hayden, Sander J van Deventer,[...]. Mol Ther Nucleic Acids 2016
51
13



RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
Scott Q Harper, Patrick D Staber, Xiaohua He, Steven L Eliason, Inês H Martins, Qinwen Mao, Linda Yang, Robert M Kotin, Henry L Paulson, Beverly L Davidson. Proc Natl Acad Sci U S A 2005
487
7

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Lisa M Stanek, Sergio P Sardi, Bryan Mastis, Amy R Richards, Christopher M Treleaven, Tatyana Taksir, Kuma Misra, Seng H Cheng, Lamya S Shihabuddin. Hum Gene Ther 2014
93
7

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
Jerry R Mendell, Samiah Al-Zaidy, Richard Shell, W Dave Arnold, Louise R Rodino-Klapac, Thomas W Prior, Linda Lowes, Lindsay Alfano, Katherine Berry, Kathleen Church,[...]. N Engl J Med 2017
772
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.